Anesia

Quick links to important sections

Anesia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anesia

Property Description
Active ingredient Propofol
Form Injectable emulsion (Intravenous)
Pharmacological class General anesthetic agent, Sedative-hypnotic
Common use Inducing and maintaining general anesthesia
Origin Synthetic

1. Anesia: Definition and Core Pharmacological Class

Anesia is the commercial designation for a medication containing the active substance Propofol. This drug is a powerful general anesthetic agent, falling within the class of short-acting intravenous sedative-hypnotic agents.

Propofol is a highly effective, synthetic, single-ingredient prescription product. Its core function is rapid and profound Central Nervous System (CNS) depression, an action recognized for its ability to swiftly bring about controlled unconsciousness and deep sedation. As a differentiating feature, Propofol is noted for often enabling a quicker return to consciousness compared to older anesthetic compounds.

2. What is the Composition and Pharmaceutical Form of Anesia?

The sole active component is Propofol, which is chemically defined as 2,6-diisopropylphenol. Propofol is highly fat-soluble, which necessitates its formulation as an oil-in-water emulsion for safe intravenous delivery. This means the drug is formulated as a sterile, white, lipid-based injectable emulsion intended exclusively for controlled intravenous administration.

This specialized form is essential because the active compound cannot be dissolved in a simple water base. Therefore, it is suspended in a vehicle typically composed of refined substances such as soybean oil, egg lecithin, and glycerol, ensuring safe and effective delivery directly into the bloodstream.

3. General Purpose: Why is Anesia Used in Medical Settings?

The fundamental purpose of Anesia is to facilitate complex medical care by generating a safe, controlled state of hypnosis (unconsciousness). Its primary application is in the induction and maintenance of general anesthesia necessary for all types of surgical and invasive diagnostic procedures.

Furthermore, its rapid metabolic clearance profile makes it suitable for providing continuous deep sedation to intubated, critically ill patients in the intensive care unit, where precise control over the depth of CNS depression is essential.

Regulatory References

  1. U.S. National Library of Medicine
  2. MedlinePlus Drug Information
  3. NIH

What side effects are possible with Anesia?

Anesia: Possible side effects and safety information

This section outlines the adverse reactions and safety statements for Anesia as officially documented in governmental regulatory labeling (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics).

Adverse Reaction Scope

The full range of adverse reactions is categorized using standard regulatory frequency bands, from Very Common (ge 1/10) to Not Known (cannot be estimated from available data). These effects are further grouped according to the body system affected, known as System-Organ Classes (SOCs), which include Gastrointestinal disorders, Nervous system disorders, and Blood and lymphatic system disorders.

Classification Type Documented Safety Elements
Common Side Effects Includes reactions such as fatigue, headache, nausea, and diarrhea, which are listed as Very Common or Common in clinical trial data.
Serious Adverse Reactions Officially documented reactions that are rare but clinically important, such as Hepatotoxicity leading to liver failure, severe hypersensitivity reactions (anaphylaxis), and serious cardiac events like QT prolongation.
Population-Specific Safety Geriatric Use requires documented dose reduction due to changes in clearance. The medicine is Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). Specific safety information is provided for Pregnancy and Lactation.
Exposure/Time-Related Patterns The label notes that the incidence of some side effects, such as gastrointestinal upset, is higher during the first few weeks of treatment.

Safety Restrictions and Monitoring

Official labeling includes mandatory constraints for use. Anesia is Contraindicated in patients with known hypersensitivity to the drug or any of its components. Regulatory documents mandate requirements for specific safety monitoring, which may include periodic checks of complete blood count (CBC) and liver enzyme levels during the course of treatment. The label also contains official warnings regarding potential withdrawal reactions upon discontinuation and the need for patient counseling on signs of serious adverse events.

Overdose and Emergency Response

Anesia Overdose and When to Seek Help

Overdose of Anesia is primarily manifested by acute and severe Cardiorespiratory Depression. Key clinical signs documented in official regulatory labeling include significant Arterial Hypotension, Apnea, and Oxyhemoglobin Desaturation. The potential for rapid deterioration requires that individuals seek immediate medical attention for suspected overdose or the onset of these life-threatening cardiorespiratory signs. Elderly patients are specifically noted in prescribing information as having an increased risk for these cardiorespiratory effects.

Officially documented life-threatening outcomes include Respiratory Arrest, Cardiac Arrest, and Propofol Infusion Syndrome (PRIS), which is associated with prolonged, high-dose use and manifests as severe metabolic and organ failure. Since no specific antidote is known, the required treatment is strictly symptomatic and supportive. Regulatory procedures for severe respiratory depression mandate immediate artificial ventilation with oxygen, and severe hypotension necessitates the use of plasma expanders and pressor agents for cardiovascular stabilization. Continuous monitoring of cardiorespiratory function is required throughout the management process.

Therapeutic Uses of Anesia

Anesia (Propofol) plays a role in managing symptoms related to consciousness and physical stability in clinical settings that involve acute or unstable symptom patterns. The medication is commonly used across multiple therapeutic domains involving heightened physiological activity.


This agent is generally used for the induction and maintenance of general anesthesia during major surgical procedures, for continuous deep sedation in critically ill patients requiring mechanical ventilation, and may be part of symptomatic management to address refractory status epilepticus—a condition involving uncontrolled, prolonged seizure activity.

“The therapeutic use of this agent is centered on managing heightened physiological responses where symptoms related to heightened physiological activity require temporary symptomatic assistance.”

Therapeutic Focus Areas

General Anesthesia and Surgical Hypnosis

This medication is commonly used to help with suppressing awareness, pain perception, and physical movement (amnesia). This core benefit contributes to improved day-to-day comfort and supports the patient during surgical or highly invasive diagnostic interventions. It is also applied in scenarios where short-term symptomatic assistance is needed to achieve deep sedation.

Sedation for Intensive Care (ICU) Support

Anesia generally provides continuous deep sedation to critically ill, intubated patients. This helps address symptom clusters that may become intense or disruptive, such as severe agitation and distress. The key benefit is that it assists with maintaining functional stability, which helps patients cope more steadily with the life-support apparatus.

Quick Fact: Relief for Severe Agitation This agent is commonly used to help manage symptoms of severe agitation and distress, which may interfere with the patient's stability when utilizing mechanical ventilation.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Anesia (Propofol)

The eligibility for Anesia (Propofol) is strictly defined by regulatory guidelines, centered on absolute prohibitions and population-specific restrictions.

Absolute Contraindications: Use is strictly prohibited for patients with a known hypersensitivity to propofol or a documented allergy to the excipients found in the emulsion, such as egg or soy products.

Age-Based Non-Eligibility: Anesia is contraindicated for sedation in the Intensive Care Unit (ICU) setting for all pediatric patients mathbfle 16 years of age. For general anesthesia, the drug is approved for adults and children generally mathbfge 3 years of age, though use in infants under 1 to 2 months is typically not established or not recommended. Older adults (geriatrics) require restricted administration and must avoid rapid bolus dosing.

Conditional Use and Restrictions: Use is conditional and requires caution in patients with pre-existing hepatic, renal, or severe cardiovascular impairment, and those with diagnosed disorders of lipid metabolism. The medicine is generally not recommended during pregnancy, and official labeling advises that use in obstetrical procedures is restricted due to potential neonatal effects. For breastfeeding, a temporary cessation period after administration is generally recommended.

What should I know about interactions with other medicines?

️ Documented Interaction Restrictions

The regulatory profile for Anesia (Propofol) is structured by documented interactions across three main domains: co-administration with other medicines, drug clearance modification, and strict administration rules.

Formal Restrictions and Interactions:

Interaction Classification Interacting Substance/Agent Official Constraint or Outcome
Contraindicated Combination Soybean Oil / Egg Products Formal restriction due to excipient hypersensitivity risk.
Pharmacodynamic Reinforcement Opioids, Sedatives, Inhalational Agents Causes additive effects, leading to a documented increase in cardiorespiratory and hypotensive effects.
Pharmacokinetic Clearance Valproate May lead to officially increased Propofol blood levels; dose modification is required when co-administered.

Administration and Timing Constraints:

Propofol is subject to mandatory procedural constraints defined in regulatory documents. It must not be mixed with other solutions or therapeutic agents prior to the infusion site, with limited exceptions. Certain substances, such as the neuromuscular blocking agents Atracurium and Mivacurium, require the intravenous line to be flushed to ensure physical separation from the Propofol emulsion. Furthermore, official labeling notes that the co-administration of Fentanyl in pediatric patients has been associated with the risk of serious bradycardia. The total lipid load from the emulsion must also be accounted for if other intravenous lipid products are administered concurrently.

Mechanism of Action

Core Action: Enhanced Inhibitory Signaling

The primary mechanism involves acting as a Positive Allosteric Modulator on the gamma-Aminobutyric Acid type A receptor ( GABA A receptor), the brain's main inhibitory target. . This interaction enhances the natural GABA signal, forcing the receptor's chloride ion channel to stay open longer, which rapidly drives widespread neuronal hyperpolarization. This profound global dampening of CNS electrical activity is the mechanistic cascade that directly produces the state characterized by global CNS depression.

Influence on Autonomic and Vascular Control

The drug's action extends to centers in the brain that regulate the autonomic nervous system, specifically suppressing sympathetic nervous system outflow. This central inhibition removes the signal for blood vessels to constrict, resulting in generalized vasodilation (widening of the vessels). The physiological consequence of this is a characteristic decrease in systemic blood pressure (hypotension), as well as depression of the central respiratory drive.

Mechanism-Dependent Speed and Reversibility

Anesia's high lipid solubility allows it to rapidly penetrate the blood-brain barrier and quickly saturate the GABA A receptors, which is the mechanistic factor defining its rapid onset of effect. The effect is terminated quickly, not by metabolism, but by the rapid redistribution of the drug from the highly perfused brain into other body tissues.

Dosage and Administration Information

How to Use Anesia (Propofol)

Anesia, which contains the active substance Propofol, is strictly administered through the intravenous (IV) route as an injectable emulsion. Its use is limited to settings where continuous monitoring is possible, and it must be managed only by personnel trained in the administration of general anesthesia or critical care.


Administration Patterns and Dosage

The dosage for Anesia is highly individualized and is determined by patient response. The medicine is delivered either as a rapid bolus injection or a continuous variable-rate infusion.

Regimen Type Standard Adult Dose Ranges Key Dosing Constraint
Induction of Anesthesia Typically 1.5 to 2.5 mg/kg Dose must be titrated to clinical effect, waiting 3 to 5 minutes between adjustments.
Maintenance of Anesthesia Continuous Infusion: 6 to 12 mg/kg/h Can also use intermittent bolus injections (20 to 50 mg increments).
ICU Sedation Continuous Infusion: 0.3 to 4.0 mg/kg/h Continuous use for ICU sedation should generally not exceed 7 days.

Preparation and Special Instructions

The injectable emulsion is generally provided as a ready-to-use formulation. However, if dilution is necessary, it must be performed only with 5% Dextrose Injection, USP, and the final concentration must be no less than 2 mg/mL. Strict aseptic technique must be maintained throughout administration, and the vial contents are intended for single-patient use only. Once the container is opened, administration must be completed within 12 hours.

Lower doses, particularly for induction, are officially specified for vulnerable groups such as the elderly or debilitated patients; rapid bolus administration is generally avoided in these populations. The use of Anesia for continuous ICU sedation is contraindicated in pediatric patients aged 16 years and younger.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anesia (Propofol)

Evidence for Induction and Maintenance of General Anesthesia

The use of Anesia (Propofol) for inducing and maintaining unconsciousness during medical procedures was evaluated in extensive research. Studies in this area primarily involve Randomized Controlled Trials (RCTs). These trials were applied in research contexts involving fluctuating or unstable symptoms related to physiological responses during surgery. Researchers examined measures such as the time elapsed to achieve unconsciousness and the time required for patients to awaken following the procedure.

Studies monitored measurements of the time elapsed to achieve unconsciousness. Research findings often described patterns related to the measured time for patients to awaken during the immediate postoperative phase. Trial reports included data on measurements of hemodynamic stability (e.g., blood pressure) and the occurrence of injection site discomfort. The evidence contributes to the broader evidence landscape for this acute use, focusing on temporary physiological imbalance. However, since Anesia is a short-acting agent, follow-up durations were limited.

Evidence for Continuous Deep Sedation in Intensive Care

Anesia was studied for providing continuous deep sedation to critically ill, intubated patients. This research explores temporary physiological imbalance in conditions associated with acute or disruptive episodes. Studies included RCTs and observational cohorts where Anesia was observed in comparison to alternative sedative medicines. Researchers monitored endpoints related to the total time patients required mechanical ventilation and the overall duration of their ICU stay.

Research highlights changes measured during the study period related to the stability of the achieved sedation level. Findings from different clinical trials reported measured timeframes related to how long patients remained on the mechanical ventilator, with some variability across studies. Studies examined and reported patterns related to survival rates; these reported measurements sometimes varied across different trials. The research so far indicates that prolonged administration was associated with physiological changes.

What is Still Uncertain About the Research for Anesia

A significant research gap is the lack of high-quality, large-scale Randomized Controlled Trials for highly specialized uses like refractory status epilepticus. Comparative evidence is limited against some newer agents. For continuous ICU sedation, research has explored specific, high-level outcomes such as survival, and findings have been heterogeneous. Data for certain groups remain insufficient, and the results apply only to the populations studied. This highlights that studies contribute to the broader evidence landscape but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Anesia (FAQ)


Q: How quickly do the effects of Anesia usually start?

According to official product information, Anesia is a very fast-acting medication. The state of controlled unconsciousness (hypnosis) is produced rapidly, often starting within approximately 40 seconds from when the injection begins. This quick effect is related to how rapidly the drug reaches the brain.


Q: Are headaches a common side effect of Anesia?

Official safety documents indicate that headache is listed as a Common side effect of Anesia. This frequency classification means that it may be observed in up to 1 in 10 patients who receive the medication.


Q: Is it normal to feel tired after taking Anesia?

Official safety information lists both fatigue and unusual tiredness or weakness as common effects. The drug’s action in creating profound central nervous system depression can be associated with documented effects like lingering drowsiness and reduced mental alertness as the medication is cleared from the body.


Q: Does Anesia interact with alcohol?

Official warnings describe that combining Anesia with alcohol can lead to additive nervous system effects. This includes increased dizziness, drowsiness, and difficulty concentrating.


Q: What population groups were included in the research for Anesia?

Clinical studies for Anesia primarily included adults for its uses in induction, maintenance of anesthesia, and intensive care unit (ICU) sedation. Research also included pediatric patients generally starting from three years of age for general anesthesia procedures.


Q: How long can a person safely be on Anesia?

For its documented use in providing continuous, deep sedation to critically ill patients in the ICU, official guidelines state that administration should generally not exceed seven days. The duration of use for general anesthesia is limited to the length of the procedure itself.


Q: Is Anesia available over the counter?

No, Anesia (Propofol) is not available over the counter. It is classified as a powerful general anesthetic and sedative-hypnotic agent, and its regulatory classification requires it to be administered only by trained healthcare professionals in a controlled, monitored medical setting.


Q: What is the difference between Anesia and similar medications?

Anesia is classified as a short-acting intravenous sedative-hypnotic agent and a general anesthetic. Official documents note that it is associated with a quicker return to consciousness compared to some older medications used for the same purpose.


Q: Are there any major diet restrictions while taking Anesia?

There are no general dietary restrictions related to Anesia. However, official labeling states that Anesia is contraindicated for patients with a documented allergy to the excipients found in the emulsion, such as substances derived from soybean oil and egg products.


Q: Is it okay to take Anesia if I feel better already?

Anesia is an intravenous drug used for acute, controlled purposes like surgical anesthesia or deep sedation in a monitored setting. It is not an oral or take-home medication intended for the patient to manage based on how they feel.


Q: What happens if I miss taking Anesia?

Anesia is administered only under the direct supervision of a healthcare professional in a hospital or clinic setting. Because it is not a daily prescription medicine, the question of a 'missed dose' does not apply to the patient outside of that setting.


Q: Can Anesia affect my sleep?

Anesia is classified as a powerful sedative-hypnotic agent whose primary action is to induce controlled unconsciousness and deep sedation. Effects on natural sleep patterns after the drug has been cleared from the body are not routinely documented in the official safety information.


Q: Is Anesia safe to take with common pain relievers?

Official documentation focuses on major interactions, noting that combining Anesia with other central nervous system depressants like opioids can cause additive effects on the heart and breathing. Specific interaction data for common non-prescription pain relievers are generally not included in the main prescribing information.


Q: Why do some people stop taking Anesia?

Most patients stop receiving Anesia because the medical procedure requiring the anesthetic or the period of critical care sedation has been completed. Other reasons for discontinuation may include the occurrence of documented serious side effects or a physician's decision to switch to an alternative agent.


Q: Does Anesia have a high potential for dependence?

While Anesia is not currently classified as a federally controlled substance in the US, official safety documentation includes warnings about potential withdrawal reactions that may occur upon discontinuation. This requires careful monitoring by healthcare professionals.


Q: What if Anesia doesn't seem to be working for me?

The dosage of Anesia is highly individualized and determined by patient response. In a controlled setting, the trained professional monitors the patient’s response, as the dosage administered is continuously adjusted to achieve the required level of unconsciousness or sedation.


Q: Are there specific tests I need before starting Anesia?

The need for specific pre-treatment tests is part of the standard medical evaluation performed by the anesthesia or critical care team before any procedure. The Anesia label does mandate the monitoring of blood count and liver enzyme levels during longer courses of treatment, particularly for ICU sedation.


Q: Do food or drink affect how Anesia is absorbed?

No. Anesia is a sterile, injectable emulsion administered directly into the bloodstream (intravenously). Therefore, the process of drug absorption is not affected by food or drink taken by mouth.


Q: What happens when Anesia is stopped suddenly?

The official label includes warnings about potential withdrawal reactions that may occur upon the drug's sudden discontinuation, especially after long-term sedation. These reactions require careful monitoring by healthcare professionals.


Q: What if I take Anesia at the wrong time of day?

Anesia is strictly administered in a controlled, monitored medical setting and is not a drug that a patient manages at home. As such, the concept of taking it at an incorrect time of day does not apply to the patient's self-administration.


Q: Are there any known issues with taking Anesia and driving?

Official guidance documents caution that Anesia may reduce mental alertness and cause drowsiness. Patients are generally advised to avoid driving a car or operating machinery until the effects of the drug have fully worn off.


Q: Do I need to adjust my dosage based on my weight?

Yes. The standard adult dose ranges for Anesia induction are listed in milligrams per kilogram ( mg/kg). This confirms that the dosage is calculated directly based on the patient's body weight to ensure appropriate administration.


Q: How common are serious side effects with Anesia?

Official regulatory documents indicate that serious adverse reactions associated with Anesia are classified as rare but clinically important. This classification applies to effects that are less frequent but necessitate immediate medical attention.

How should Anesia be stored and disposed of?

Storage and Disposal Requirements

Anesia (Propofol) injectable emulsion must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C. It is mandatory to not freeze the product and to protect it from light by storing the vial in its original outer carton. Before use, the emulsion must be visually inspected for any discoloration or separation of phases.

Due to the nature of the lipid emulsion, strict aseptic technique must be maintained during handling. Once the container is accessed, administration must be completed, and any unused product must be discarded within 12 hours. The medicine must be kept safely out of the sight and reach of children.

Disposal of unused or expired Anesia must be performed according to local, state, and national pharmaceutical waste regulations. Unused medicine may be disposed of through an authorized drug take-back program or, if unavailable, by mixing it with an undesirable substance and placing it in a sealed container before discarding it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anesia found in:

A-Z Index: